Early Detection of Pancreatic and Colorectal Cancers via Ultra-Sensitive Circulating Tumor DNA (ctDNA) Analysis

Open Journal of Clinical Diagnostics, Journal Year: 2025, Volume and Issue: 15(02), P. 29 - 45

Published: Jan. 1, 2025

Language: Английский

---

Liquid Biopsy in Hepatocellular Carcinoma: ctDNA as a Potential Biomarker for Diagnosis and Prognosis

Current Oncology Reports, Journal Year: 2025, Volume and Issue: unknown

Published: May 9, 2025

Abstract Purpose of Review Hepatocellular carcinoma (HCC) is a leading cause cancer-related mortality worldwide, with rising incidence and mortality. Early-stage HCC often asymptomatic, the lack reliable early diagnostic markers leads to late-stage diagnosis limited treatment options. Current relies on tumour staging patient status, but accurate requires invasive procedures that fail capture heterogeneity progression. There an urgent need for less strategies, such as liquid biopsy technologies, which allow repeated sampling real-time analysis dynamics. Liquid biopsies, including circulating cells (CTCs) DNA (ctDNA), offer potential monitor recurrence, metastasis, responses, potentially transforming clinical management by enabling earlier intervention personalised strategies. Recent Findings studies emphasise ctDNA non-invasive biomarker targeting methylation detection, timely improve outcomes. Comparative analyses have shown mutation testing outperforms alpha-fetoprotein (AFP), sensitivity 85% specificity 92%, compared 60% 80% AFP. Additionally, profiling landscape 100 patients has identified recurrent mutations in genes TP53, CTNNB1, AXIN1. Summary appears be promising patients, improving 41.67% 15% respectively. The mutations, particularly those methylation, highlight great precision medicine, critical prognosis HCC.

Language: Английский

---

Circulating Tumor DNA and Management of Colorectal Cancer

Cancers, Journal Year: 2023, Volume and Issue: 16(1), P. 21 - 21

Published: Dec. 19, 2023

Although the incidence of colorectal cancer (CRC) has decreased as a result increased screening and awareness, it still remains major cause cancer-related death. Additionally, early detection CRC recurrence by conventional means such CT, endoscopy, CEA not translated into an improvement in survival. Liquid biopsies, circulating tumor DNA (ctDNA), have been investigated biomarker for patients with terms prognosis recurrence, well their use to guide therapy. In this manuscript, we provide overview ctDNA its utility providing prognostic information, using therapy, monitoring CRC. addition, discuss influence site disease may on ability detect metastatic

Language: Английский

---

Optimising Deep Neural Networks for Tumour Diagnosis Algorithms Based on Improved MRFO Algorithm

EAI Endorsed Transactions on Pervasive Health and Technology, Journal Year: 2024, Volume and Issue: 10

Published: April 8, 2024

INTRODUCTION: Cancer has become one of the most prevalent diseases with highest mortality rate in world, and timely detection early acceptance medical therapeutic interventions are effective means controlling progression cancer patients improving their post-intervention outcomes.OBJECTIVES: To make defects incomplete features, low accuracy real-time performance current tumour diagnosis methods.METHODS: This paper proposes a method based on improved MRFO algorithm to improve optimization process DBN network parameters. Firstly, diagnostic features extracted by analysing identification problem; then, manta ray foraging is combining good point set initialization strategy, adaptive control parameter strategy distribution estimation model optimize parameters depth confidence constructed; finally, high proposed verified analysis simulation experiments.RESULTS: The results show that improves model.CONLUSION: Addresses problem poor availability methods.

Language: Английский

---

Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials

Translational Oncology, Journal Year: 2023, Volume and Issue: 37, P. 101763 - 101763

Published: Aug. 30, 2023

Up to 430,000 cases of bladder cancer are diagnosed each year worldwide. A proposed method for non-invasive monitoring has been utilize a "liquid biopsy." Liquid biopsy as testing biomarkers in bodily fluids order detect and survey cancer. The liquid could be utilized obtain information regarding circulating tumor cells, cell-free DNA, RNA, more. It is currently being investigated help guide adjuvant therapy improve oncological outcomes. We highlight an array exciting past ongoing clinical trials ctDNA regard urothelial carcinoma which we believe amongst the leaders field.

Language: Английский

---

Pilot Study by Liquid Biopsy in Gastrointestinal Stromal Tumors: Analysis of PDGFRA D842V Mutation and Hypermethylation of SEPT9 Presence by Digital Droplet PCR

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(12), P. 6783 - 6783

Published: June 20, 2024

Tissue biopsy remains the standard for diagnosing gastrointestinal stromal tumors (GISTs), although liquid is emerging as a promising alternative in oncology. In this pilot study, we advocate droplet digital PCR (ddPCR) to diagnose GIST tissue samples and explore its potential early diagnosis via biopsy, focusing on PDGFRA D842V mutation SEPT9 hypermethylated gene. We utilized ddPCR analyze predominant (D842V) surgical from 15 patients, correlating with pathologists’ diagnoses. expanded our analysis plasma compare DNA alterations between tumor plasma, also investigating gene hypermethylation. successfully detected tissues by ddPCR. Despite various protocols enhance detection early-stage disease, it remained challenging, likely due low concentration of samples. Additionally, results Area Under Curve (AUC) gene, analyzing concentration, ratio, abundance were 0.74 (95% Confidence Interval (CI): 0.52 0.97), 0.77 CI: 0.56 0.98), 0.79 0.59 0.99), respectively. As rare through such biomarkers particularly crucial, offering significant improve patient outcomes.

Language: Английский

---

Treatment Classification by Intent in Oncology—The Need for Meaningful Definitions: Curative, Palliative and Potentially Life-Prolonging

Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(9), P. 932 - 932

Published: Aug. 31, 2024

Realistic cancer treatment goals should be used by health care professionals and communicated to patients, families, the public. The current nomenclature on this subject is outdated has not been changed since advent of modern oncology in middle 20th century.

Language: Английский

---

Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not?

World Journal of Clinical Oncology, Journal Year: 2022, Volume and Issue: 13(12), P. 980 - 983

Published: Dec. 16, 2022

The evaluation of circulating tumor DNA (ctDNA) is increasingly integrated into the management diagnosis and treatment gastrointestinal cancer as it represents an innovative minimally invasive biomarker that could allow us to reach clinical needs not met yet in randomized trials. Recent research provided interesting overview role gastric, biliary, liver, pancreatic, colorectal cancer. Data regarding upper tumors are currently practice changing. Tumor detection rates low early stages, while advanced stages ctDNA useful for molecular tracking evaluation. Most evidence comes from studies, where was evaluated both with post-surgery minimal residual disease assessment response assessment, respectively. qualifies a promising tool era precision medicine, potential applications entire patients. Further needed establish which setting may be influenced greatly by liquid biopsy practice.

Language: Английский

---

Personalized decision making of neoadjuvant chemotherapy vs. upfront surgery in pancreatic cancer by a simple blood collection?

memo - Magazine of European Medical Oncology, Journal Year: 2024, Volume and Issue: 18(1), P. 49 - 52

Published: Dec. 18, 2024

Language: Английский

---